ZYBERNO
Stock Report
Updated Sep 1, 2026

BIOLARGO, INC. (BLGO)

Materials • OTC

$0.10

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
7.0/100
POOR BUSINESS
BIOLARGO, INC. (BLGO) scores 7/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-4,120.8%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-444.0%)
Return on Capital (Capital Efficiency):CRITICAL (-303.3%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

BIOLARGO, INC. (BLGO) stock report — Zyberno Score 7/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.10
Market Cap:$31.44M

Valuation Multiples (2)

P/S Ratio:7.70x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$31.25M

Price Action & Momentum (3)

Momentum Percentile:9 / 100
% of 52-Week High:41.9%
B. Profitability Assessment

Return Metrics (5)

ROA:-230.0%
Reinvestment Rate:1.1%
Fundamental Growth Rate (g):-3.2%

Margin Analysis (3)

Operating Margin Ttm:-444.0%
Net Margin Ttm:-460.3%
Ebitda Margin:-440.7%

TTM Performance (3)

Gross Margin Ttm:39.9%
Operating Margin Ttm:-444.0%
Net Margin Ttm:-460.3%

Yield Metrics (2)

Earnings Yield:-$29.56
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:100.0%
Latest Earnings Filed:2022-03-31

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-18.8%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.73x
Quick Ratio:0.67x
Cash Ratio:0.46x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-17.50x
Times Interest Earned:-17.50

Capital Structure (4)

Working Capital:-1,266,000.00
Cash And Cash Equivalents:2,188,000.00
Long Term Debt:$746.00K
Net Debt:-$195.00K
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $4.08M
Linear Growth: -18.8%
📊 Click to view full BLGO Revenue analysis & methodology →
Cost Of Revenue Ttm:$2.45M

Profitability Breakdown (2)

Gross profit TTM: $1.63M
Linear Growth: -25.7%
📊 Click to view full BLGO Gross Profit analysis & methodology →
-$18.12M

Bottom Line Performance (3)

-$18.79M
Income Before Tax:-$15.19M
Ebitda Ttm:-17,991,000.00

Operating Expenses (5)

Operating Expenses:19,753,000.00
R And D Expense:3,262,000.00
Sga Expense:12,591,000.00
Income Tax Expense:$0.00
Interest Expense:868,000.00

Expense Ratios (3)

R And D To Revenue Percentage:261.4%
Sga To Revenue Percentage:1,008.9%
Ebitda Margin:-440.7%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$6.67M
Current Assets:$3.50M
Ppe Net:1,768,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:9,399,000.00
Current Liabilities:4,765,000.00
Long Term Debt:$746.00K
Short Term Debt:$1.25M

Equity & Capital (3)

Equity:-$2.73M
Retained Earnings:-$166.33M
Common Stock:550,000,000.00

Working Capital Items (3)

Accounts Receivable:724,000.00
Inventory:303,000.00
Accounts Payable:874,000.00

Special Items (2)

Contract Liabilities:46,000.00
Stock Based Compensation:699,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$9.38M$0.00

Investment Activities (1)

Investing Cash Flow:-$32.00K

Financing Activities (3)

Financing Cash Flow:$3.19M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:256,000.00
Long Term Debt Issuance:$280.00K
Long Term Debt Repayments:$8.00K

Non-Cash Items (1)

Depreciation Amortization Ttm:132,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.05
-$0.03
Earnings Per Share Ttm:-$0.06

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.01
Operating Cash Flow Per Share:-$0.03

Book Value & Capital (2)

Book Value Per Share:-$0.01
Cash Per Share:0.01

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.50x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:5.64x
Days Sales Outstanding Ttm:64.74

Inventory Management (2)

Inventory Turnover Ttm:8.09x
Days Inventory Outstanding Ttm:45.10

Payables & Cash Cycle (2)

Days Payable Outstanding:130.10
Cash Conversion Cycle:-20.26
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:1.1%
Fundamental Growth Rate (g):-3.2%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-18.8%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):-25.7%
Book Value Growth Rate (Linear):15.2%
C. Company Profile & Context

Corporate Information (6)

Symbol:BLGO
Company Name:BIOLARGO, INC.
Sector:Materials
Industry:Chemicals
Exchange:OTC
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:320.98M
Shares Outstanding Basic:320.98M
Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 04:03:46 UTC
Data Timestamp:2026-08-20T12:39:52.798346
Scroll to Top